San Diego Stock Exchange

SEARCH SAN DIEGO STOCKS:

Symbol

CYPRESS BIOSCIENCE INC

Symbol	Name	Close	Change		Volume	Dayhigh	Daylow
CYPB	Cypress Bio	5.53	-0.01	- 0.18%	537571.00	5.69	5.51

Exchange	Earningspershare	52-Week High	52-Week Low
NASDAQ N-Mkt	-0.48	10.10	4.98

SourceBook Information

Cypress Bioscience Inc. is listed in:

• Biomed & Biotech Firms -
• Biomed & Biotech Firms - Publicly Traded -
• Highest Paid CEOs of BIO Tech Companies -
• Local Publicly Traded Companies -

Contact Information

Company Name

Cypress Bioscience Inc.

Executives

Jay D. Kranzler, Chairman/CEO

R. Michael Gendreau, CMO/VP, Development

Denise Woolard, VP, Business & Legal Affairs

Sabrina Martucci Johnson, VP/CFO

Srinivas G. Rao, M.D., Ph.D. – Chief Scientific Officer

Address

4350 Executive Drive, Suite 325

San Diego, CA 92121

Phone

(858) 452-2323

Fax

(858) 452-1222

E-mail

ir-info@cypressbio.com

Web Page

www.cypressbio.com

Business Information

Parent Company

n/a

Business Description

Provides products for the treatment of patients with functional somatic syndromes, such as fibromyalgia syndromes and other related chronic pain and central nervous systems disorders.

SIC Code

n/a

Headquarters

San Diego, CA

Local Mailing Address

4350 Executive Drive, Suite 325, San Diego, CA 92121

Year Established

1981

Year Established in San Diego

1981

Publicly Traded?

Yes

Ticker Symbol

CYPB

Total Number of Employees

14

Number of Local Employees

14

Number of Offices Local

1

Business Services

Drug development

Industries of Interest

n/a

Market Capitalization

$266,870,600

Gross Revenue 2000 Year End

$2,975,000

Gross Revenue 2000

wnd

Gross Revenue 2001 Year End

$1,600,000

Gross Revenue 2001

wnd

Gross Revenue 2002 Year End

wnd

Gross Revenue 2002

wnd

Gross Revenue 2003 Year End

wnd

Gross Revenue 2003

$0

Gross Revenue 2004

$14,400,000

Gross Revenue 2005 YTD, Local

$5,500,000

Gross Revenue 2007

n/a

Manufacturer

No

Fields of Research

Providing products for the treatment of patients with functional somatic syndromes and other central nervous system disorders

Major Products

Milnacipran and other drugs and drug development

Major Investors

Deerfield Management, JP Morgan; Barclays Global Investors

Number of Products Approved For Sale

0

Patents

n/a

Number of Products In Development

2

Strategic Alliances

Forest Laboratories, Organon

Services Offered

n/a

Chief Executive Officer

Jay D. Kranzler

Date CEO Began

1995

Total Annual CEO Compensation (salary & bonuses)

$495,000 (FY 2004)

CEO Salary

$495,000 (FY 2004)

CEO Bonuses

$0 (FY 2004)

Gross Revenue 2006

n/a

Sales for 2006

n/a

Gross Revenue 2008

n/a

Mission Statement

Looking forward, we are continuing to evaluate other various potential strategic transactions, including the potential acquisitions of products, technologies and companies, and other alternatives.